Potential drug-drug interactions in prescriptions dispensed in community pharmacies in Greece

Pharmacy World and Science

Volumn 32, Issue 2, 2010, Pages 187-193

  Chatsisvili, Anna ^a   Sapounidis, Ioakeim ^a   Pavlidou, Georgia ^a   Zoumpouridou, Eudoxia ^a   Karakousis, Vasileios Alexandros ^a   Spanakis, Marios ^a   Teperikidis, Lefteris ^a   Niopas, Ioannis ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Community pharmacies; Drug drug interactions; Greece; Prescriptions

Indexed keywords

ACENOCOUMAROL; AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; POTASSIUM SPARING DIURETIC AGENT; POTASSIUM WASTING DIURETIC AGENT; SIMVASTATIN; UNCLASSIFIED DRUG; VERAPAMIL;

ADVERSE OUTCOME; ARTICLE; CARDIOVASCULAR DISEASE; DESCRIPTIVE RESEARCH; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG SURVEILLANCE PROGRAM; GREECE; HUMAN; HYPERKALEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; MYOPATHY; PATIENT SAFETY; PHARMACEUTICAL CARE; PHARMACIST; PRESCRIPTION; PROSPECTIVE STUDY; QT PROLONGATION; RHABDOMYOLYSIS; RISK ASSESSMENT;

ADVERSE DRUG REACTION REPORTING SYSTEMS; COMMUNITY PHARMACY SERVICES; DRUG INTERACTIONS; GREECE; HEALTH SERVICES RESEARCH; HUMANS; PRESCRIPTION DRUGS; PROSPECTIVE STUDIES;

EID: 77953323076     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-010-9365-1     Document Type: Article

References (40)

1. Hansten PD, Horn JR. Drug Interactions Analysis and Management, Facts & Comparisons. Philadelphia, PA: Lippincott Williams & Wilkins; 2009. ISBN: 10: 1-57439-311-8.
2. Becker ML, Kallewaard M, Caspers PW, Schalekamp T, Stricker BH. Potential determinants of drug-drug interaction associated dispensing in community pharmacies. Drug Saf. 2005;28: 371-8.
3. Linnarsson R. Drug interactions in primary health care: a retrospective database study and its implications for the design of a computerized decision support system. Scand J Prim Health Care. 1993;11:181-6.
4. Bergendal L, Friberg A, Schaffrath A. Potential drug-drug interactions in 5.125 mostly elderly out-patients in Gottenburg, Sweden. Pharm World Sci. 1995;17:152-7.
5. Merlo J, Liedholm H, Lindblad U, Bjorck-Linne A, Falt J, Lindberg G, et al. Prescriptions with potential drug interactions dispensed at Swedish pharmacies in January 1999: cross sectional study. BMJ. 2001;323(7310):427-8.
6. Colley CA, Lucas LM. Polypharmacy: the cure becomes the disease. J Gen Intern Med. 1993;8:278-83.
7. Bjerrum L, Andersen M, Petersen G, Kragstrup J. Exposure to potential drug interactions in primary health care. Scand J Prim Health Care. 2003;21:153-8.
8. Jankel CA, Fitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf. 1993;9: 51-9.
9. Huic M, Mucolic V, Vrhovac B, Francetic I, Bakran I, Giljanovic S. Adverse drug reactions resulting in hospital admission. Int J Clin Pharmacol Ther. 1994;32:675-82.
10. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002;36: 1331-6.
11. Peyriere H, Cassan S, Floutard E, Riviere S, Blayac JP, Hillaire-Buys D, et al. Adverse drug events associated with hospital admission. Ann Pharmacother. 2003;37:5-11.
12. Becker ML, Caspers PW, Kallewaard M, Bruinink RJ, Kylstra NB, Heisterkamp S, et al. Determinants of potential drug-drug interaction associated dispensing in community pharmacies in the Netherlands. Pharm World Sci. 2007;29:51-7.
13. Abarca J, Colon LR, Wang VS, Malone DC, Murphy JE, Armstrong EP. Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmacies. J Manag Care Pharm. 2006;12:383-9.
14. Weideman RA, Bernstein IH, McKinney WP. Pharmacist recognition of potential drug interactions. Am J Health Syst Pharm. 1999;56:1524-9.
15. Glassman PA, Simon B, Belperio P, Lanto A. Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care. 2002;40:1161-71.
16. Tzimis L, Katsantonis N, Leledaki A, Vasilomanolakis K, Kafatos A. Prescribed medication and nutrition of social care patients in Crete, Greece. Public Health. 1996;110:361-7.
17. Tzimis L, Katsantonis N, Leledaki A, Vasilomanolakis K, Kafatos A. Antibiotics prescription for indigent patients in primary care. J Clin Pharm Ther. 1997;22:227-35.
18. Tzimis L, Kafatos A. Drug utilization and health behaviours among indigent elderly patients in Crete, Greece. Pharmacoepidemiol Drug Saf. 1999;8:105-14.
19. Antonakis N, Xylouri I, Alexandrakis M, Cavoura C, Lionis C. Seeking prescribing patterns in rural Crete: a pharmacoepidemiological study from a primary care area. Rural Remote Health. 2006;6:488.
20. Drug Interactions Checker, Cerner Multum, Inc., Denver, CO. http://www.drugs.com/.
21. ATC/DDD Index. WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health, Oslo, Norway. 2009. http://www.whocc.no/ atc-ddd-Index/.
22. Hansten PD, Horn JR. The top 100 drug interactions: a guide to patient management. Freeland, WA: H & H Publications. LLP; 2009. ISBN 978-0-9819440-0-5.
23. Hansten PD, Horn JR. Drug interactions & updates. 7th ed. Vancouver, WA: Applied Therapeutics Inc.; 1992. ISBN-10: 0-8121-1381-0.
24. Cruciol-Souza JM, Thomson JC. A pharmacoepidemiologic study of drug interactions in a Brazilian teaching hospital. Clinics (Sao Paulo). 2006;61:515-20.
25. Janchawee B, Wongpoowarak W, Owatranporn T, Chongsuvivatwong V. Pharmacoepidemiologic study of potential drug interactions in outpatients of a university hospital in Thailand. J Clin Pharm Ther. 2005;30(1):13-20.
26. Chiu TF, Bullard MJ, Chen JC, Liaw SJ, Ng CJ. Rapid life-threatening hyperkalemia after addition of amiloride HCl/hydrochlorothiazide to angiotensin-converting enzyme inhibitor therapy. Ann Emerg Med. 1997;30:612-5.
27. Antonelli D, Atar S, Freedberg NA, Rosenfeld T. Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions. Isr Med Assoc J. 2005;7:163-5.
28. Roten L, Schoenenberger RA, Krahenbuhl S, Schlienger RG. Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother. 2004;38:978-81.
29. Siddoway LA. Amiodarone: guidelines for use and monitoring. Am Fam Physician. 2003;68:2189-96.
30. Astrand B, Montelius E, Petersson G, Ekedahl A. Assessment of ePrescription quality: an observational study at three mail-order pharmacies. BMC Med Inform Decis Mak. 2009;9:8.
31. Murphy JE, Malone DC, Olson BM, Grizzle AJ, Armstrong EP, Skrepnek GH. Development of computerized alerts with management strategies for 25 serious drug-drug interactions. Am J Health Syst Pharm. 2009;66:38-44.
32. Cusack CM. Electronic health records and electronic prescribing: promise and pitfalls. Obstet Gynecol Clin North Am. 2008;35: 63-79.
33. Jani YH, Ghaleb MA, Marks SD, Cope J, Barber N, Wong IC. Electronic prescribing reduced prescribing errors in a pediatric renal outpatient clinic. J Pediatr. 2008;152:214-8.
34. Rupp MT, Warholak TL. Evaluation of e-prescribing in chain community pharmacy: best-practice recommendations. J Am Pharm Assoc. 2008;48:364-70.
35. Venkatraman R, Durai R. Errors in medicine administration: how can they be minimised? J Perioper Pract. 2008;18:249-53.
36. Carroll NV. Do community pharmacists influence prescribing? J Am Pharm Assoc. 2003;43:612-21.
37. Heikkila T, Lekander T, Raunio H. Use of an online surveillance system for screening drug interactions in prescriptions in community pharmacies. Eur J Clin Pharmacol. 2006;62:661-5.
38. Tamblyn R, Huang A, Perreault R, Jacques A, Roy D, Hanley J, et al. The medical office of the 21st century (MOXXI): effectiveness of computerized decision-making support in reducing inappropriate prescribing in primary care. CMAJ. 2003;169: 549-56.
39. Vonbach P, Dubied A, Krahenbuhl S, Beer JH. Evaluation of frequently used drug interaction screening programs. Pharm World Sci. 2008;30:367-74.
40. Hazlet TK, Lee TA, Hansten PD, Horn JR. Performance of community pharmacy drug interaction software. J Am Pharm Assoc (Wash). 2001;41:200-4.